Walleye Capital LLC Acquires Shares of 18,425 AnaptysBio, Inc. $ANAB

Walleye Capital LLC acquired a new position in shares of AnaptysBio, Inc. (NASDAQ:ANAB) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 18,425 shares of the biotechnology company’s stock, valued at approximately $1,022,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in shares of AnaptysBio by 4.5% in the 4th quarter. Vanguard Group Inc. now owns 1,544,037 shares of the biotechnology company’s stock valued at $74,855,000 after purchasing an additional 67,048 shares in the last quarter. State Street Corp lifted its holdings in AnaptysBio by 20.6% during the 4th quarter. State Street Corp now owns 1,053,474 shares of the biotechnology company’s stock worth $51,072,000 after buying an additional 180,042 shares during the last quarter. 683 Capital Management LLC lifted its stake in AnaptysBio by 18.5% during the fourth quarter. 683 Capital Management LLC now owns 648,093 shares of the biotechnology company’s stock worth $31,420,000 after purchasing an additional 101,093 shares during the last quarter. Affinity Asset Advisors LLC acquired a new position in AnaptysBio in the fourth quarter worth $21,559,000. Finally, Goldman Sachs Group Inc. increased its stake in AnaptysBio by 20.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 398,914 shares of the biotechnology company’s stock valued at $19,339,000 after purchasing an additional 69,094 shares during the last quarter.

Analyst Ratings Changes

Several analysts recently issued reports on ANAB shares. Piper Sandler cut their price target on AnaptysBio from $95.00 to $93.00 and set an “overweight” rating on the stock in a report on Monday, May 4th. Weiss Ratings lowered AnaptysBio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 13th. HC Wainwright began coverage on AnaptysBio in a research report on Wednesday, June 10th. They set a “buy” rating and a $95.00 price objective for the company. Barclays lifted their target price on shares of AnaptysBio from $63.00 to $75.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 13th. Finally, Leerink Partners set a $90.00 price objective on AnaptysBio in a research note on Friday, May 15th. Nine analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $82.00.

AnaptysBio Price Performance

Shares of ANAB stock opened at $54.15 on Friday. AnaptysBio, Inc. has a fifty-two week low of $11.40 and a fifty-two week high of $72.36. The stock’s 50-day moving average is $58.38 and its two-hundred day moving average is $57.47. The firm has a market cap of $1.60 billion, a P/E ratio of -50.14 and a beta of 0.68.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported ($1.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($1.20). The firm had revenue of $25.56 million during the quarter, compared to analyst estimates of $18.86 million. As a group, research analysts expect that AnaptysBio, Inc. will post -1.35 EPS for the current year.

AnaptysBio declared that its Board of Directors has approved a stock buyback program on Friday, March 27th that allows the company to buyback $100,000.00 billion in outstanding shares. This buyback authorization allows the biotechnology company to reacquire up to 5,352,316.2% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.